Genmab prepares to race Roche with new main candidate

Genmab CEO Jan van de Winkel has great confidence in cancer drug epcoritamab, which is slated to be the company's new golden goose, but the head start of competitor Roche should ideally be reduced while the firm works to expand its pipeline.

Photo: Stine Bidstrup/ERH

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles